← All trials
NCT04879589
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 10, 2021
- Primary completion
- Nov 10, 2021
- Completion date
- Dec 28, 2021
- First posted
- May 10, 2021
- Last posted
- May 10, 2021
- Enrollment
- 32
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Syneos HealthLead sponsor
- Antares Pharma Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.